{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:02:56Z","timestamp":1789657376236,"version":"4.0.1"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["STA00059"],"award-info":[{"award-number":["STA00059"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Following two fatal adverse reactions after yellow fever (YF) vaccination in the United Kingdom (UK) between 2018 and 2019, both involving unapproved use, the UK Medicines and Healthcare products Regulatory Agency (MHRA) mandated that the Marketing Authorisation Holder incorporate a checklist into the YF vaccine (STAMARIL) Risk Management Plan. This checklist was implemented as part of the local additional risk minimisation measures (aRMMs) in 2021, along with an updated patient information leaflet (PIL), to assist UK healthcare professionals (HCPs) in conducting risk\u2010benefit evaluations during YF vaccination consultations. We evaluated the effectiveness of these interventions among HCPs at authorised YF vaccination centres and vaccinees across the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a cross\u2010sectional online survey among eligible UK HCPs and YF vaccinees in 2023, we assessed five effectiveness indicators: four for HCPs (aRMMs YF pre\u2010vaccination checklist awareness, standardised YF pre\u2010vaccination checklist utilisation, PIL distribution and knowledge and understanding of checklist's key safety messages) and one for vaccinees (PIL receipt). Each indicator was successful if achieved by \u2265\u200980% of the respondents. The proportion of desirable answers provided for each indicator with 95% confidence interval (CI) was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 153 HCPs who responded, 73.9% (95% CI: 66.4%\u201380.2%) were aware of the aRMMs checklist, 89.5% (95% CI: 83.7%\u201393.5%) utilised any standardised checklist(s), 92.2% (95% CI: 86.8%\u201395.5%) distributed the PIL to vaccinees and 46.4% (95% CI: 38.7%\u201354.3%) provided desirable answers to \u2265\u200980% of the questions on knowledge and understanding of key safety messages. Among 125 vaccinees who responded, 87.2% (95% CI: 80.2%\u201392.0%) confirmed PIL receipt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Three of the five effectiveness indicators were successful. Importantly, no YF vaccination errors were reported in the UK National Travel Health Network and Centre Annual Return reports (2021\u20132024) following aRMM implementation. Therefore, these findings suggest that the local aRMMs provide an effective framework for the safe administration of YF vaccine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70359","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:05:47Z","timestamp":1774868747000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of the Local Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey of Healthcare Professionals and Vaccinees"],"prefix":"10.1002","volume":"35","author":[{"given":"Leila","family":"Karimi","sequence":"first","affiliation":[{"name":"Real World Solutions IQVIA  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artis","family":"Luguzis","sequence":"additional","affiliation":[{"name":"Real World Solutions IQVIA  Riga Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Pawar","sequence":"additional","affiliation":[{"name":"Real World Solutions IQVIA  Gurugram India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Dufournet","sequence":"additional","affiliation":[{"name":"Global Biostatistical Sciences Sanofi  Marcy l'Etoile France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Morelli","sequence":"additional","affiliation":[{"name":"Global Medical Sanofi  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Thollot","sequence":"additional","affiliation":[{"name":"Global Medical Sanofi  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Caroline","family":"Guichard","sequence":"additional","affiliation":[{"name":"Medical Operations and Effectiveness Sanofi  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillemette","family":"Petti","sequence":"additional","affiliation":[{"name":"Patient Safety &amp; Pharmacovigilance Sanofi  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3972-735X","authenticated-orcid":false,"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"Epidemiology and Benefit Risk Sanofi  Morristown New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090891"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2015.1083430"},{"key":"e_1_2_12_4_1","unstructured":"\u201cCountries With Risk of Yellow Fever Transmission and Countries Requiring Yellow Fever Vaccination (November 2022) \u201d 2022 https:\/\/www.who.int\/publications\/m\/item\/countries\u2010with\u2010risk\u2010of\u2010yellow\u2010fever\u2010transmission\u2010and\u2010countries\u2010requiring\u2010yellow\u2010fever\u2010vaccination\u2010november\u20102022."},{"key":"e_1_2_12_5_1","unstructured":"\u201cDrug Safety Update \u201d 2019;13(4):1 https:\/\/www.gov.uk\/drug\u2010safety\u2010update\/yellow\u2010fever\u2010vaccine\u2010stronger\u2010precautions\u2010in\u2010people\u2010with\u2010weakened\u2010immunity\u2010and\u2010in\u2010those\u2010aged\u201060\u2010years\u2010or\u2010older."},{"key":"e_1_2_12_6_1","unstructured":"\u201cInternational Health Regulations (2005) \u2013 Third Edition \u201d 2016 https:\/\/www.who.int\/publications\/i\/item\/9789241580496."},{"key":"e_1_2_12_7_1","unstructured":"\u201cPublic Health Scotland \u201d accessed February 10 2022 https:\/\/publichealthscotland.scot\/population\u2010health\/health\u2010protection\/immunisation\u2010vaccine\u2010and\u2010preventable\u2010disease\/yellow\u2010fever\u2010vaccination\u2010centres\/resources\u2010for\u2010the\u2010public\/."},{"key":"e_1_2_12_8_1","unstructured":"\u201cNaTHNaC Yellow Fever Zone \u201d accessed February 16 2026 https:\/\/nathnacyfzone.org.uk\/."},{"key":"e_1_2_12_9_1","unstructured":"\u201cNotice: Yellow Fever Vaccination Centres \u2013 Annual Return (1 January\u201331 December 2025) \u201d 2025 https:\/\/nathnacyfzone.org.uk\/pdf\/news.php?nid=199."},{"key":"e_1_2_12_10_1","unstructured":"\u201cDrug Safety Update \u201d 2021;15(4):1 https:\/\/www.gov.uk\/drug\u2010safety\u2010update\/yellow\u2010fever\u2010vaccine\u2010stamaril\u2010new\u2010pre\u2010vaccination\u2010checklist."},{"key":"e_1_2_12_11_1","unstructured":"\u201cCommission on Human Medicines\u2010Report of the Commission on Human Medicine's Expert Working Group on Benefit\u2010Risk and Risk Minimisation Measures of the Yellow Fever Vaccine \u201d Independent Report 2019 https:\/\/www.gov.uk\/government\/publications\/report\u2010of\u2010the\u2010commission\u2010on\u2010human\u2010medicines\u2010expert\u2010working\u2010group\u2010on\u2010benefit\u2010risk\u2010and\u2010risk\u2010minimisation\u2010measures\u2010of\u2010the\u2010yellow\u2010fever\u2010vaccine."},{"key":"e_1_2_12_12_1","unstructured":"\u201cNaTHNaC\/PHS\u2010Yellow Fever Pre\u2010Vaccination Checklist \u201d 2021 https:\/\/travelhealthpro.org.uk\/factsheet\/87\/yellow\u2010fever\u2010pre\u2010vaccination\u2010checklist."},{"key":"e_1_2_12_13_1","unstructured":"\u201cGVP Module XVI (Rev.3)\u2014Risk Minimisation Measures (RMM) and Methods for Effectiveness Evaluation \u201d 2025 https:\/\/isoponline.org\/wp\u2010content\/uploads\/2025\/12\/S18.1\u2010RMM\u2010effectiveness\u2010evaluation\u2010methods_T\u2010Goedecke_15Oct2025.pptx.pdf."},{"issue":"1","key":"e_1_2_12_14_1","article-title":"339. Evaluating Effectiveness of Risk Minimization Through Healthcare Professional Education: A Literature Review","volume":"34","author":"Zhu K.","year":"2025","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"e_1_2_12_15_1","unstructured":"\u201cSurvey Methodologies to Assess REMS Goals That Relate to Knowledge\u2014Guidance for Industry \u201d 2019 https:\/\/www.fda.gov\/media\/119789\/download."},{"key":"e_1_2_12_16_1","unstructured":"IQVIA \u201cOnekey by Iqvia\u2010Healthcare Professionals Data \u201d 2022 https:\/\/www.onekeydata.com\/onekey\/healthcare\u2010professionals\u2010data."},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-017-0591-5"},{"key":"e_1_2_12_18_1","first-page":"372","article-title":"Evaluation of the Effectiveness of Risk Minimisation Measures Targeting Physicians on Prescribing Practices of Thiocolchicoside Containing Medicinal Products for Systemic Use","volume":"9","author":"Jouaville L. S.","year":"2019","journal-title":"Epidemiology (Sunnyvale)"},{"key":"e_1_2_12_19_1","unstructured":"\u201cNaTHNaC\u2010Annual Return \u201d 2022 https:\/\/nathnacyfzone.org.uk\/media_lib\/mlib\u2010uploads\/full\/yellow\u2010fever\u2010annual\u2010return\u2010report\u20102022.pdf."},{"key":"e_1_2_12_20_1","unstructured":"\u201cNaTHNaC\u2010Annual Return \u201d 2023 https:\/\/nathnacyfzone.org.uk\/media_lib\/mlib\u2010uploads\/full\/yellow\u2010fever\u2010annual\u2010return\u2010report\u20102023.pdf."},{"key":"e_1_2_12_21_1","unstructured":"\u201cNaTHNaC\u2010Annual Return \u201d 2024 https:\/\/nathnacyfzone.org.uk\/media_lib\/mlib\u2010uploads\/full\/yellow\u2010fever\u2010annual\u2010return\u2010report\u20102024.pdf."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1612875"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-017-0184-8"},{"key":"e_1_2_12_24_1","unstructured":"\u201cGuideline on Good Pharmacovigilance Practices (GVP) Module XVI \u2013 Risk\u2010Minimisation Measures (Rev 3) \u201d 2024 https:\/\/www.ema.europa.eu\/en\/documents\/regulatory\u2010procedural\u2010guideline\/guideline\u2010good\u2010pharmacovigilance\u2010practices\u2010gvp\u2010module\u2010xvi\u2010risk\u2010minimisation\u2010measures\u2010rev\u20103_en.pdf."},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4434"},{"key":"e_1_2_12_26_1","unstructured":"\u201cNaTHNaC\u2010Annual Return \u201d 2019 https:\/\/nathnacyfzone.org.uk\/news\/103\/yellow\u2010fever\u2010vaccination\u2010centre\u2010annual\u2010return\u2010report\u20102019."},{"key":"e_1_2_12_27_1","unstructured":"\u201cNaTHNaC\u2010Annual Return \u201d 2020 https:\/\/travelhealthpro.org.uk\/news\/572\/notice\u2010yellow\u2010fever\u2010vaccination\u2010centres\u2010\u2010annual\u2010return\u2010for\u2010yfvcs\u20101\u2010january\u2010\u201031\u2010december\u20102020."},{"key":"e_1_2_12_28_1","unstructured":"\u201cNaTHNaC\u2010Annual Return \u201d 2021 https:\/\/nathnacyfzone.org.uk\/news\/120\/notice\u2010yellow\u2010fever\u2010vaccination\u2010centres\u2010\u2010annual\u2010return\u2010for\u2010yfvcs\u20101\u2010january\u2010\u201031\u2010december\u20102021."},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/poq\/nfi002"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0197-0"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0619-x"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70359","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70359","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:05:20Z","timestamp":1789653920000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/pds.70359"],"URL":"https:\/\/doi.org\/10.1002\/pds.70359","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"2025-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70359"}}